Following the exploration of centralized procurement of proprietary Chinese medicines in 19 provinces led by Hubei and the Guangdong Proprietary Chinese Medicine Collective Procurement Alliance, the national centralized procurement of proprietary Chinese medicines, which has attracted much attention in the industry, has finally been launched
recently.
On September 8, the National Joint Procurement Office of Proprietary Chinese Medicines was officially established, and the "Procurement Announcement of the National Alliance of Proprietary Chinese Medicines" was issued, with a total of 30 provinces participating in the procurement of the National Proprietary Chinese Medicine Alliance, covering six therapeutic areas
: internal medicine, orthopedic medicine, ophthalmic medicine, tumor medicine, cardiovascular system medicine and gynecological medicine.
The industry believes that this large-scale collection of proprietary Chinese medicines is regarded as the national centralized procurement of proprietary Chinese medicines, the centralized procurement of proprietary Chinese medicines will be normalized, the price reduction of proprietary Chinese medicines may become a trend, and the reshuffle of the entire industry will accelerate in the future, forming a pattern
of "the strong and the strong".
Some small and medium-sized Chinese medicine enterprises that do not have strong research and development capabilities and mainly rely on a small number of varieties may face elimination
.
In the face of the pattern changes brought about by the normalization of centralized procurement of proprietary Chinese medicines, the industry suggests that Chinese medicine enterprises should actively participate in centralized procurement and make responses, such as increasing the research and development of new drugs and developing more good drugs
.
It is reported that many Chinese medicine companies have taken action
.
For example, on the evening of December 28, 2021, the company announced that it had signed a "strategic cooperation agreement" with Beijing Yingkerui to fully carry out R&D cooperation in proprietary Chinese medicines, and signed a technology transfer contract with its wholly-owned subsidiary Yingkerui (Tianjin) Innovative Pharmaceutical Research Co.
, Ltd.
("Tianjin Yingkerui") on the "Class 1.
1 Innovative Pharmacology Anti-rejection Granules".
Share the benefits
of future drugs after they are approved.
Yiling Pharmaceutical is also increasing its research and development of innovative Chinese medicines, and as of February this year, 11 innovative varieties of traditional Chinese medicines have been approved for marketing
.
In the past two years, Yiling Pharmaceutical has successfully developed 3 traditional Chinese medicines, and a number of new Chinese medicine drugs are in the review and clinical stage, according to Guosen Securities and Kaiyuan Securities, Yiling Pharmaceutical will maintain the rhythm
of 1-2 approvals every year.
According to the data of Southwest Securities Research Report, from the current conventional speed, it takes about 0.
5 years to declare IND, about 1 year to declare NDA, and more than 3 years for clinical trials (phase 2 + 3), if all are well connected, a Chinese medicine innovative drug will take more than
4.
5 years.
However, since the drug review reform in 2015, the quality of innovative Chinese medicine applications has been greatly improved, and innovative varieties of traditional Chinese medicines have been approved for marketing, of which the number of listings reached 12 in 2021, a new high
.
The industry reminds that in the future, pharmaceutical companies need to improve the effectiveness and safety of their products in order to take the lead
in the new situation.
In addition, the R&D of traditional Chinese medicines carries uncertain risks, and it is still necessary to be vigilant against the losses
caused by R&D failure.
In addition to new drug research and development, many enterprises have responded to collective procurement
through mergers and acquisitions.
For example, at the end of May this year, China Resources Sanjiu issued an announcement that the company intends to purchase 209 million shares and 3.
3355 million shares
of Kun Pharmaceutical Group held by it from Holley Pharmaceutical and Holley Group for about 2.
9 billion yuan.
After the completion of this transaction, Kun Pharmaceutical Group will become a holding subsidiary
of China Resources Sanjiu.
For this transaction, CR Sanjiu believes that it is conducive to improving the company's profitability, enhancing its comprehensive competitiveness and anti-risk ability, and helping to improve the company's asset quality and profitability, and enhance its ability
to continue operation.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
